https://www.medpagetoday.com/meetingcov ... 669819d41r
"This is a large effect in the device 1 group, particularly as it is on top of background treatment," Craft said. "At 18 months, the results show a prolonged, statistically significant benefit for the insulin-treated group who used device 1 that strengthens over time, with a pattern consistent with a disease-modifying effect."
Cerebrospinal fluid analysis showed the Aβ42/40 ratio (P=0.01) and Aβ42/tau ratio (P=0.03) also improved for people treated with device 1. (Aβ42 and Aβ40 are the 42- and 40-amino acid forms of the amyloid-beta protein.)
"It's encouraging to see that if you do get insulin to the brain, you see changes in biomarkers," said Laurie Ryan, PhD, Chief of the Dementias of Aging Branch of the National Institute on Aging, which funded the study. "That's important, but it needs to be tested," she told MedPage Today. "It's got to go to a larger phase III study."